- Record: found
- Abstract: found
- Article: found
Myoinositol – a Uremic Neurotoxin?
A. Blumberg , E. Esslen , W. Bürgi
02 December 2008
Abstract
In 28 patients predialysis plasma myoinositol was significantly elevated to 10.8 ± 2.: versus 0.75 ± 0.15 mg/100 ml in normals (mean ± 1 SD), and was weakly correlated with plasm; creatinine concentrations (r = 0.42, p < 0.05). Dialysis decreased plasma myoinositol con centrations to 3.5 ± 1.1 mg/100 ml. In 16 patients studied more extensively plasma myoinosito was similarly elevated to 10.6 ± 3.4 mg/100 ml, and spinal fluid myoinositol was increased t < 9.4 ± 2.3 mg/100 ml (versus 2.7 ± 0.7 in normals, p < 0.001). Nerve conduction velocities wer reduced in 15 and EEG tracings were abnormal in 12 of the 16 patients. However, neither spins fluid nor plasma myoinositol showed any correlation with nerve conduction velocities or EEG changes (r = 0.05–0.20, NS) Myoinositol is one of the substances retained in renal insufficiency but no indication was found that it is a toxin causing uremic neurological disturbances.
Related collections
Author and article information
Journal
Affiliations
Article
181392 Nephron 1978;21:186–191Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.